OKYO Pharma

We are committed to developing next-generation therapies for individuals suffering from corneal neuropathic pain and rare corneal disease. Our aim is to create innovative therapies that not only alleviate ocular pain but also address the limitations of current treatments by offering a novel approach to controlling inflammation.

OKYO Pharma is committed to developing investigational therapies through carefully conducted clinical trials so that their safety and effectiveness can be properly evaluated and regulatory approval can be obtained.

OKYO’s lead drug candidate, Urcosimod (0.05%), is a novel, non-opioid, preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity for neuropathic corneal pain (NCP)

OKYO Pharma Limited (Incorporated and registered in Guernsey with registered number 65220) Allotment of Ordinary Shares and Listing Application OKYO Pharma Limited (LSE:OKYO) (the “Company”) today announces that pursuant to an agreement dated 22 October 2018 between the Company and On Target Therapeutics LLC (“On Target”) amending the collaboration agreement dated 4 June 2018 between […]

OKYO Pharma Limited(Incorporated and registered in Guernsey with registered number 65220) Expected Admission Date for Consideration Shares OKYO Pharma Limited (LSE:OKYO) (the “Company“) today announces that in connection with its announcement on 24 October 2018 (the “24 October Announcement”), regarding its agreement to allot 512,866 ordinary shares of no par value in the capital of […]

OKYO Pharma Limited Interim results for the six months to 30 September 2018 OKYO Pharma Limited (LSE:OKYO) (the “Company“) is pleased to announces interims results for the six months to 30 September 2018. Financial Highlights Total Assets decreased to £1.3 million (30 September 2017: £2.0 million). Cash on hand equates to £1.2 million (30 September […]

NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Okyo Pharma Limited 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer X 2. Reason for the notification (please mark the appropriate box […]

OKYO Pharma Limited (“OKYO” or the “Company”) is pleased to announces that Gregor MacRae has been appointed as a non-executive director of the company with immediate effect. Leopoldo Zambeletti is simultaneously standing down as a director of the Company with immediate effect. Gregor is a business adviser, who specialises in taxation and cross border solutions. […]

Mr Cerrone has a successful track record and extensive experience in the financing and restructuring of micro-cap biotechnology companies. He has founded ten biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has taken seven of these companies to the NASDAQ Market and two to the Main Market and AIM Market in London. Mr […]

Dr. Jacob has over 35 years of extensive experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations, business development, capital financing activities and senior management expertise. He has developed broad and influential contacts throughout the biopharmaceutical, financial, banking and investor communities. Dr. Jacob is the Co-Founder and former CEO […]

Keeren Shah serves as our Chief Financial Officer. Ms. Shah currently also serves as the Finance Director of Tiziana Life Sciences LTD, Accustem Sciences Limited and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining the Company, Ms. Shah spent 10 […]

OKYO Pharma Ltd. (NASDAQ: OKYO) is an emerging clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. The Company is committed to addressing significant unmet medical needs through innovative science, targeted therapeutic approaches, and a disciplined clinical and regulatory development strategy.

Thank you for your interest in OKYO Pharma Ltd. Please fill out the form below with any questions or comments and we will get back to you soon.

Urcosimod is a novel class of chemerin (ChemR23 or CMKLR1) receptor agonist that produces an anti-inflammatory and reduction in neuropathic pain.

OKYO Pharma Limited (the “Company”, “we”, “us” or “our”) is committed to protecting your privacy and the security of your personal data (“Personal Data” or “Personal Information”). This is our privacy policy (the “Privacy Policy”) which explains why and how we process your Personal Data, and your rights and how to contact us if you need to.

This website and any related or linked documents (the “Website”) is the website of OKYO Pharma Limited (the “Company”, “us” or “we”).

25 September 2020 In accordance with paragraph 9.2.6E of the Listing Rules (disclosure of rights attached to equity shares), the Company has today uploaded to the National Storage Mechanism (NSM) a copy of its Articles of Association, which set out the principal rights and restrictions attached to its ordinary shares. The NSM can be accessed […]